SCHEMBL2079031

SCHEMBL2079031

O=C1c2ccccc2-c2c(Br)cccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRC P08575 3/20 0.57
ADORA2A P29274 2/20 0.57
MAPT P10636 9/20 0.57
ALDH1A1 P00352 9/20 0.57
MEN1 O00255 6/20 0.57
KMT2A Q03164 6/20 0.57
L3MBTL1 Q9Y468 6/20 0.57
POLB P06746 4/20 0.57
HTT P42858 3/20 0.57
CDC25B P30305 1/20 0.55
KEAP1 Q14145 3/20 0.50
NFE2L2 Q16236 2/20 0.50
MAOA P21397 5/20 0.48
MAOB P27338 2/20 0.48
RAB9A P51151 4/20 0.48
NPC1 O15118 3/20 0.48
NSD2 O96028 2/20 0.48
MAPK1 P28482 7/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
TDP1 Q9NUW8 4/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29679284 1.00 PTPRC (0.57) PTPRCADORA2AMAPTALDH1A1MEN1
SCHEMBL472644 0.91 ADORA2A (0.57) PTPRCADORA2AMAPTALDH1A1MEN1
Ammonia Solution, Strong SCHEMBL27798139 0.89 ADORA2A (0.55) PTPRCADORA2AMAPTALDH1A1MEN1
Methane SCHEMBL4593466 0.89 ADORA2A (0.55) PTPRCADORA2AMAPTALDH1A1MEN1
SCHEMBL15678555 0.88 CA1 (0.52) PTPRCADORA2AMAPTALDH1A1MEN1
SCHEMBL5412322 0.86 MAPT (0.54) PTPRCADORA2AMAPTALDH1A1MEN1
Methylamine SCHEMBL9597386 0.85 ADORA2A (0.57) PTPRCADORA2AMAPTALDH1A1MEN1
SCHEMBL6904504 0.83 MAOA (0.52) PTPRCADORA2AMAPTALDH1A1MEN1
SCHEMBL1325322 0.82 PTPRC (0.58) PTPRCADORA2AMAPTALDH1A1MEN1
SCHEMBL17852136 0.82 ALDH1A1 (0.44) PTPRCADORA2AMAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108863694-A A method of synthesis 9,9`- spirobifluorene derivative 新乡市润宇新材料科技有限公司 2018-11-23 CN claimed
CN-105237379-A Production method for 4-bromo fluorenone INST CHEMISTRY CO LTD HENAN ACADEMY OF SCIENCES 2016-01-13 CN claimed
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMA INC (US) 2026-03-05 US disclosed
US-12486230-B2 Materials for organic electroluminescent devices MERCK PATENT GMBH (DE) 2025-12-02 US disclosed
US-20250282709-A1 SPIROBIFLUORENE COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2025-09-11 US disclosed
CN-115141173-B Compound and organic electroluminescent device comprising the same 浙江虹舞科技有限公司 2025-03-18 CN disclosed
CN-112654613-B Condensed-cyclic compound and organic light-emitting device comprising same 株式会社LG化学 2025-02-07 CN disclosed
US-12167685-B2 Organic compounds and organic light emitting display device using the same LG DISPLAY CO., LTD. (KR) 2024-12-10 US disclosed
CN-118812412-A Preparation method of spirotrienone and coumarin and derivatives thereof 黄淮学院 2024-10-22 CN disclosed
EP-4438693-A2 HETEROCYCLIC SPIRO COMPOUNDS Merck Patent GmbH (DE) 2024-10-02 EP disclosed
EP-3708634-B1 HETEROCYCLIC SPIRO COMPOUNDS MERCK PATENT GMBH (DE) 2024-08-14 EP disclosed
US-20100130503-A1 NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 SANOFI-AVENTIS (FR) 2010-05-27 US disclosed
US-20100130503-A1 NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 SANOFI-AVENTIS (FR) 2010-05-27 US disclosed
US-7674795-B2 Fluorene derivatives, composition containing said derivatives and the use thereof AVENTIS PHARMA SA (FR) 2010-03-09 US disclosed
EP-2078009-A1 NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 Sanofi-Aventis (FR) 2009-07-15 EP disclosed
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-26 US disclosed
WO-2008049994-A1 NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 SANOFI-AVENTIS (FR) 2008-05-02 WO disclosed
EP-1888579-A2 NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF Aventis Pharma S.A. (FR) 2008-02-20 EP disclosed
WO-2006123061-A2 FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF AVENTIS PHARMA S.A. (FR) 2006-11-23 WO disclosed
EP-0886182-A1 Positive photoresist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062443-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C9, SSB, C1S PTPRC 1602/4885ADORA2A 3496/4885MAPT 1355/4885
US-12486230-B2 Materials for organic electroluminescent devices L1CAM, EFNA1, EPCAM PTPRC 3741/4885ADORA2A 4011/4885MAPT 1786/4885
US-20100130503-A1 NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 HSP90AB2P, HSPA2, HSP90AB1 PTPRC 1524/4885ADORA2A 3671/4885MAPT 1323/4885
US-20250282709-A1 SPIROBIFLUORENE COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES PKD1, PIEZO1, AQP1 PTPRC 2487/4885ADORA2A 4117/4885MAPT 2656/4885
US-12167685-B2 Organic compounds and organic light emitting display device using the same AOX1, OCIAD1, SLCO2A1 PTPRC 1407/4885ADORA2A 2979/4885MAPT 1420/4885
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof HSP90B1, HSP90AB1, HSP90AA1 PTPRC 1389/4885ADORA2A 3575/4885MAPT 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.